/

Società

Al

Non verificato

Alpha Cognition, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

4 comunicati stampa

Guarda tutti i comunicati

16/06/2026

Industria

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease

Fonte

Alpha Cognition, Inc.

Emittente

1.00

0

27/04/2026

Salute

Sanità

Medicina - Varie

Farmaceutica

Biotecnologia

Web e Social Network

Fiere

Eventi

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

Fonte

Alpha Cognition, Inc.

Emittente

1.00

0

07/01/2026

Biotecnologia

Farmaceutica

Salute

Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution

Fonte

Alpha Cognition, Inc.

Emittente

1.00

0

08/01/2025

Biotecnologia

Psichiatria

Salute

Farmaceutica

Mercato del lavoro

Industria

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

Fonte

Alpha Cognition, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0